Bio-S: Innovative drug BIOS-0623-Z4 tablets have received clinical trial approval
I'm PortAI, I can summarize articles.
Bio-S announced that its independently developed innovative drug BIOS-0623-Z4 tablets have received clinical trial approval from the National Medical Products Administration (NMPA). This drug targets cancer pain in adults and employs a non-opioid target mechanism, with no other drugs on the market targeting the same mechanism and indication. BIOS-0623-Z4 tablets are classified as Category 1 chemical drugs and are innovative drugs that have not been launched domestically or internationally
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments